Blackstone closes record $6.3bn life sciences fund
Blackstone has closed its latest fund – the $6.3bn BXLS VI – saying it is the largest ever private fund for the life sciences sector.
Newsletters and Deep Dive digital magazine
Blackstone has closed its latest fund – the $6.3bn BXLS VI – saying it is the largest ever private fund for the life sciences sector.
Kailera Therapeutics has filed for an IPO, hoping to whet investor appetites with its pipeline of drug candidates for weight loss.
Boardrooms and advisory panels across pharma, biotech, medtech, and digital health were busy last month.
Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.
Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.
Editor's Picks
Newsletters and Deep Dive
digital magazine